Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Capital Expenditures: 2011-2024

Historic Capital Expenditures for Iovance Biotherapeutics (IOVA) over the last 13 years, with Dec 2024 value amounting to $11.1 million.

  • Iovance Biotherapeutics' Capital Expenditures rose 373.95% to $10.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.7 million, marking a year-over-year increase of 175.01%. This contributed to the annual value of $11.1 million for FY2024, which is 50.34% down from last year.
  • Latest data reveals that Iovance Biotherapeutics reported Capital Expenditures of $11.1 million as of FY2024, which was down 50.34% from $22.3 million recorded in FY2023.
  • In the past 5 years, Iovance Biotherapeutics' Capital Expenditures ranged from a high of $46.8 million in FY2020 and a low of $11.1 million during FY2024.
  • Moreover, its 3-year median value for Capital Expenditures was $20.4 million (2022), whereas its average is $17.9 million.
  • In the last 5 years, Iovance Biotherapeutics' Capital Expenditures spiked by 576.46% in 2020 and then plummeted by 50.34% in 2024.
  • Iovance Biotherapeutics' Capital Expenditures (Yearly) stood at $46.8 million in 2020, then dropped by 19.70% to $37.6 million in 2021, then slumped by 45.64% to $20.4 million in 2022, then increased by 9.13% to $22.3 million in 2023, then crashed by 50.34% to $11.1 million in 2024.